Date added: Friday 27th April 2012
BPL is delighted to announce that the UK Marketing Authorisation for Gammaplex has been extended to include the following new indications: ITP (Immune thrombocytopenic purpura), GBS (Guillain Barré syndrome), Kawasaki disease and Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT).
In a recent, open label, Phase 3, single arm, multicentre study of 29 patients aged 6-69 years with
chronic immune thrombocytopenic purpura, Gammaplex::
Dr Tim Aldwinckle (Medical Director BPL) commented, “BPL can now offer patients with ITP a licensed treatment option to improve and maintain the platelet count and reduce the bleeding episodes. Regulatory acceptance of these results as a model for Guillain Barré syndrome and Kawasaki disease allows additional patients to benefit from this product'”
Note to Editors
For more information contact:
Bio Products Laboratory Limited
Contact number: 07881 920408
Date of preparation March 2012.
For full Press Release and Prescribing Information: